Jun. 30 at 8:43 PM
$HELP nice consolidation breather.
Gaining 10-100x you've got to pause to eat and sleep.
But make no mistake we are in the beast mode growth spurt phase (next 3-4 months) of a 18-36 month run.
DFTX is running so hard because MDD is such a massive market of desperately unmet need. We have better data for the very same market, albeit at phase 2. Ours is a:
"–23-point mean MADRS reduction from baseline at 12 months, 100% response rate, and 71% remission rate (MADRS ≤10; even higher using alternative remission thresholds), with excellent safety profile".
What do you think is going to happen as we approach our first phase 3 read out?
"As of the latest updates (June 24–29, 2026), the APPROACH Phase 3 trial has surpassed 86–88% enrollment and remains on track. The company continues to guide for topline efficacy data readout from APPROACH in Q4 2026 (October–December 2026)."
